Each month, the not-for-profit French journal Prescrire publishes systematic, independent analyses of the available evidence regarding new drugs, newly authorised indications for drugs already on the market, and new forms or new dose strengths of existing drugs.
The goal is to select, amidst the multitude of new products, those which deserve to be added to the list of useful therapeutic options, or ought to be used in place of other drugs.
The annual Prescrire Awards recognise drugs, drug packaging and drug information singled out for notice by Prescrire's editorial staff. The Prescrire Awards for 2022 in Paris were announced on 1st February 2023.
"Pilule d'Or" Awards
The "Pilule d'Or" ("Golden Pill") is granted to drugs that represent a major therapeutic advance in a field in which no treatment was previously available.
- No drug represented a major therapeutic advance
Honours List
Drugs included on the Honours List constitute a clear advance for some patients compared with existing therapeutic options, albeit with limitations.
- PAXLOVID° (nirmatrelvir + ritonavir) - Pfizer
Noteworthy
Drugs that are deemed "Noteworthy" provide a modest improvement in patient care.
- ONUREG° (azacitidine) - Bristol-Myers Squibb
For details, see:
> The Prescrire Awards for 2022
©Prescrire 1 March 2023
Source: "The Prescrire Awards" Prescrire International 2023; 32 (246): 80-81. Free.
Enjoy full access to Prescrire International, and support independent information
|